Breast cancer genetic testing is a laboratory-based molecular analysis that identifies inherited and tumor-acquired gene mutations—most notably in BRCA1 and BRCA2—that influence an individual's risk of developing breast cancer and guide personalized treatment decisions. This technical article provides a comprehensive overview of breast cancer gene testing, covering sample types, testing items, analytical methods, quality standards, clinical applications, and frequently asked questions for clinicians, laboratory professionals, and patients considering BRCA testing and hereditary cancer panel analysis.
Technical Overview
Breast cancer genetic testing encompasses a group of molecular diagnostic procedures designed to detect pathogenic germline (heritable) and somatic (tumor-acquired) variants in genes associated with breast cancer susceptibility, progression, and therapeutic response. Germline testing, typically performed on blood or saliva, identifies inherited mutations passed through family lineages, while somatic testing, performed on tumor tissue, characterizes the genomic profile of the cancer itself to inform targeted therapy selection.
The most clinically significant genes include BRCA1 and BRCA2, which are tumor suppressor genes responsible for DNA repair via homologous recombination. Pathogenic variants in these genes are associated with a cumulative lifetime breast cancer risk of approximately 45–85% and significantly elevated ovarian cancer risk. Expanded multigene panels now also assess additional moderate- and high-penetrance genes such as PALB2, TP53, CHEK2, ATM, PTEN, CDH1, STK11, NF1, and BARD1.
Modern breast cancer genetic testing is predominantly performed in accredited third-party laboratories or clinical molecular laboratories conforming to ISO 15189 (medical laboratory quality and competence) and ISO/IEC 17025 (general testing laboratory competence). Analytical validity, clinical validity, and clinical utility are governed by internationally recognized quality frameworks, with pre-test and post-test genetic counseling recommended by international clinical guidelines.
Testing Samples
Peripheral Blood
Venous blood collected in EDTA anticoagulant tubes is the preferred sample type for germline (hereditary) testing. A typical volume of 3–5 mL is sufficient for genomic DNA extraction. Blood samples should be transported at 2–8°C and processed within 72 hours to preserve DNA integrity. Leukocytes serve as the DNA source, providing a complete representation of the inherited genome.
Saliva and Buccal Swabs
Non-invasive alternatives for germline testing, saliva collection kits and buccal swabs are widely used for direct-to-consumer and remote collection scenarios. Buccal epithelial cells yield genomic DNA of adequate quality for sequencing, although samples must be collected at least 30 minutes after eating, drinking, or smoking to minimize contamination. Stabilizing reagents in commercial collection tubes allow ambient transport for extended periods.
FFPE Tumor Tissue
Formalin-fixed paraffin-embedded (FFPE) tissue blocks or sections from surgical resection or core needle biopsy are the standard specimens for somatic tumor testing. A minimum tumor cellularity of approximately 20% is generally required, determined by pathologist review on hematoxylin and eosin (H&E) stained slides. Formalin-induced cross-linking and fragmentation necessitate specialized DNA repair and quality-control workflows, and adjacent unstained sections (typically 5–10 sections at 5–10 μm thickness) accompany the block.
Fresh or Frozen Tissue
Fresh tumor tissue snap-frozen in liquid nitrogen provides the highest-quality DNA for comprehensive genomic profiling. Although less commonly archived in routine practice, fresh-frozen material is preferred for whole-exome and whole-genome sequencing applications where DNA integrity is critical.
Plasma (Circulating Tumor DNA)
Liquid biopsy using peripheral blood collected in specialized cell-stabilizing tubes enables analysis of circulating tumor DNA (ctDNA). This minimally invasive approach is valuable for treatment monitoring, assessing minimal residual disease, and genotyping patients unable to undergo tissue biopsy. Plasma separation must occur within the tube manufacturer's specified stabilization window to prevent leukocyte DNA contamination.
Testing Items
Breast cancer genetic testing portfolios are structured according to clinical purpose. The principal test categories are summarized below.
- BRCA1/BRCA2 full-gene analysis: Complete sequencing of all coding exons and exon–intron boundaries to detect single nucleotide variants (SNVs), small insertions and deletions (indels), and splice-site variants, including the recurrent founder mutations observed in specific populations.
- Large genomic rearrangement (LGR) detection: Identification of exon-level deletions and duplications in BRCA1/BRCA2 and other panel genes, which account for a meaningful proportion of pathogenic variants undetectable by sequencing alone.
- Hereditary breast cancer multigene panels: Concurrent analysis of 6 to over 80 genes, including high-penetrance genes (BRCA1, BRCA2, TP53, PTEN, CDH1, STK11, PALB2) and moderate-penetrance genes (CHEK2, ATM, NF1, BARD1, RAD51C, RAD51D, BRIP1).
- Tumor somatic mutation profiling: Detection of actionable somatic alterations in PIK3CA, ESR1, AKT1, PTEN, KRAS, and BRCA1/2 reversion mutations to guide targeted therapy and clinical trial enrollment.
- Homologous recombination deficiency (HRD) assessment: Genomic scar scores and loss-of-heterozygosity profiles evaluating functional DNA repair capacity, used to predict sensitivity to platinum chemotherapy and PARP inhibitors.
- Variant classification and reporting: Variants are interpreted according to the five-tier scheme of the American College of Medical Genetics and Genomics (ACMG) and the Association for Molecular Pathology (AMP): pathogenic, likely pathogenic, variant of uncertain significance (VUS), likely benign, and benign.
Testing Methods
Multiple complementary technologies are employed, selected based on sample type, scope of analysis, turnaround-time requirements, and sensitivity thresholds.
- Next-generation sequencing (NGS): The dominant platform for both germline panels and somatic tumor profiling. Targeted capture hybridization or amplicon-based enrichment is followed by massively parallel sequencing on short-read platforms, achieving analytical sensitivity above 99% for SNVs and indels at variant allele fractions as low as 5% (tumor) or at the heterozygous germline level. Depth of coverage typically exceeds 500× for germline and 500–1000× for somatic applications.
- Sanger sequencing: Capillary electrophoresis-based dideoxy sequencing used historically as the gold standard for BRCA1/BRCA2 analysis. It remains valuable for targeted confirmation of variants and for testing single genes or family member segregation studies.
- PCR-based assays: Allele-specific PCR (ARMS), quantitative PCR, and melting curve analysis provide rapid, cost-effective genotyping of known hotspot mutations such as recurrent founder variants.
- Digital droplet PCR (ddPCR): Ultra-sensitive quantification of known variants at allele fractions below 0.1%, applied to ctDNA monitoring, minimal residual disease tracking, and confirmation of low-frequency somatic mutations.
- Multiplex ligation-dependent probe amplification (MLPA): A targeted semi-quantitative method for detecting exon-level copy number changes (large deletions and duplications) in BRCA1, BRCA2, and other susceptibility genes, routinely performed as a complement to sequencing.
- Fluorescence in situ hybridization (FISH): Used for gene-level copy number assessment in tumor tissue, including evaluation of amplification events relevant to molecular subtyping.
- Bioinformatics pipeline: Sequencing data undergo alignment to the reference genome, base-quality recalibration, variant calling, annotation against reference databases, and computational filtering. Laboratories validate pipelines in accordance with ISO 15189 and ISO/IEC 17025 requirements, with orthogonal confirmation of reportable variants where mandated.
Quality Control and Standards
Reliable breast cancer genetic testing depends on rigorous pre-analytical, analytical, and post-analytical controls. Accredited third-party laboratories implement external quality assessment participation, internal quality control materials with known genotypes, coverage uniformity thresholds, and minimum depth requirements for every reported region. Germline reports follow ACMG/AMP variant interpretation standards, while somatic reports apply the joint AMP, American Society of Clinical Oncology (ASCO), and College of American Pathologists (CAP) tiering framework (Tier I–IV). Turnaround time typically ranges from 10 to 21 calendar days for panel testing, with statutory confidentiality protections applying to all genetic results.
Applications
Results from breast cancer genetic testing translate directly into risk management and therapeutic decision-making across multiple clinical scenarios.
- Hereditary risk assessment: Identification of pathogenic germline variants enables quantitative breast cancer risk stratification and guides enhanced surveillance programs, including annual contrast-enhanced magnetic resonance imaging initiated at earlier ages.
- Preventive interventions: Carriers of high-penetrance mutations may elect risk-reducing mastectomy or salpingo-oophorectomy, chemoprevention, or lifestyle modification after structured genetic counseling.
- Precision therapy selection: Tumors with deleterious BRCA1/BRCA2 alterations demonstrate increased sensitivity to PARP inhibitors (such as olaparib and talazoparib) and platinum-based chemotherapy. PIK3CA-mutated tumors qualify for PI3K inhibitor therapy, while HRD scores expand the eligible treatment population.
- Familial cascade testing: A positive germline result triggers predictive testing of blood relatives, allowing at-risk family members to access early surveillance before disease onset.
- Clinical trial matching: Comprehensive tumor profiling identifies patients eligible for biomarker-driven oncology trials and targeted drug programs.
- Treatment monitoring: Serial ctDNA analysis tracks therapeutic response and detects emerging resistance mutations, such as BRCA reversion variants restoring homologous recombination function.
- Life planning decisions: Pre-implantation genetic testing and prenatal counseling options are available to carriers planning reproduction.
FAQ
Who should consider breast cancer genetic testing?
Candidates include individuals diagnosed with breast cancer before age 50, those with triple-negative breast cancer before age 60, individuals with bilateral or multiple primary cancers, anyone with a strong family history of breast, ovarian, pancreatic, or prostate cancer, individuals of ancestries with known founder mutations, and male breast cancer patients. An unaffected person may also pursue testing if a close relative carries a known pathogenic variant.
What is the difference between germline and somatic testing?
Germline testing uses blood or saliva to detect inherited mutations present in every cell of the body, informing hereditary risk for the patient and family members. Somatic testing uses tumor tissue or ctDNA to identify mutations acquired within the cancer, guiding treatment of the existing tumor. Both are frequently performed for the same patient because the results answer different clinical questions.
What does a positive BRCA result mean?
A positive result indicates a pathogenic or likely pathogenic variant associated with elevated lifetime cancer risk. It does not mean cancer is certain or already present. It enables enhanced screening, preventive options, eligibility for targeted therapies such as PARP inhibitors, and informed cascade testing of relatives.
What is a variant of uncertain significance (VUS)?
A VUS is a genetic change whose association with disease risk is not yet established by current evidence. It is reported as a technical finding but does not confirm increased risk and should not drive medical decisions. VUS results are periodically reclassified as evidence accumulates, and laboratories issue updated reports when classifications change.
How accurate is breast cancer genetic testing?
In accredited laboratories, the analytical sensitivity and specificity of comprehensive BRCA1/BRCA2 testing, including sequencing plus copy number analysis, exceed 99% for detectable variant classes. Clinical sensitivity depends on the proportion of hereditary risk attributable to the genes examined, which is why expanded multigene panels improve overall diagnostic yield.
How long does testing take?
Typical turnaround time is 2 to 4 weeks for germline panel testing and 2 to 3 weeks for somatic tumor profiling from receipt of an adequate specimen. Urgent treatment-decision testing may be prioritized, while liquid biopsy assays for known variants can return results within 1 to 2 weeks.
Are genetic test results confidential?
Yes. Genetic information receives heightened legal protection in most jurisdictions, restricting its use in health insurance and employment decisions. Laboratories operate under strict data governance, and results are released only to the ordering clinician and, where authorized, to genetic counselors involved in post-test consultation.
Is genetic counseling necessary?
Pre-test counseling ensures informed consent, accurate family history documentation, and appropriate test selection. Post-test counseling supports correct interpretation of results—particularly VUS findings—psychological adaptation, risk management planning, and communication with family members regarding cascade testing.
Can testing be done after cancer treatment has started?
Yes. Germline testing remains valid regardless of treatment status because inherited DNA does not change. Somatic tumor testing, however, may be affected by prior systemic therapy, so fresh biopsy or archival tissue from before certain treatments is preferred when available.